astemizole has been researched along with cisapride in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 14 (56.00) | 29.6817 |
| 2010's | 10 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Pearlstein, R; Rampe, D; Vaz, R | 1 |
| Keserü, GM | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Bianucci, AM; Calderone, V; Coi, A; Massarelli, I; Testai, L | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Abu Khalaf, R; Abu Sheikha, G; Bustanji, Y; Taha, MO | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Sen, S; Sinha, N | 1 |
| Scott, DO; Sun, H | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Carbajo, RJ; Gozalbes, R; Melnyk, P; Mosulén, S; Ortí, L; Pineda-Lucena, A; Rodríguez-Díaz, J | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Gong, Q; January, CT; Zhou, Z | 1 |
| Brown, AM; Ficker, E; Obejero-Paz, CA; Zhao, S | 1 |
| Paakkari, I | 1 |
| Danielsson, BR; Danielsson, C; Nilsson, MF | 1 |
| Dabhi, J; Mehta, A | 1 |
| Chu, I; Margulis, M; Nomeir, AA; Priestley, T; Soares, A; Sorota, S | 1 |
| Clancy, CE; Romero, L; Saiz, J; Trenor, B; Yang, PC | 1 |
3 review(s) available for astemizole and cisapride
| Article | Year |
|---|---|
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
Topics: Cation Transport Proteins; DNA-Binding Proteins; Drug-Related Side Effects and Adverse Reactions; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Long QT Syndrome; Models, Molecular; Pharmaceutical Preparations; Potassium Channels; Potassium Channels, Voltage-Gated; Structure-Activity Relationship; Torsades de Pointes; Trans-Activators; Transcriptional Regulator ERG | 2003 |
Cardiotoxicity of new antihistamines and cisapride.
Topics: Arrhythmias, Cardiac; Astemizole; Benzimidazoles; Butyrophenones; Cetirizine; Cisapride; Heart Diseases; Histamine H1 Antagonists; Humans; Loratadine; Piperidines; Serotonin Receptor Agonists; Terfenadine; Triprolidine | 2002 |
Embryonic cardiac arrhythmia and generation of reactive oxygen species: common teratogenic mechanism for IKr blocking drugs.
Topics: Abnormalities, Drug-Induced; Animals; Anti-Arrhythmia Agents; Anticonvulsants; Arrhythmias, Cardiac; Astemizole; Cisapride; Dimethadione; Ether-A-Go-Go Potassium Channels; Female; Free Radical Scavengers; Gastrointestinal Agents; Heart; Histamine Antagonists; Humans; Hypoxia; Phenytoin; Potassium Channel Blockers; Pregnancy; Reactive Oxygen Species; Teratology; Toxicity Tests | 2007 |
22 other study(ies) available for astemizole and cisapride
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation.
Topics: Amino Acid Sequence; Heart; Humans; Models, Molecular; Molecular Sequence Data; Molecular Structure; Protein Subunits; Sequence Alignment; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
Topics: Cholesterol Ester Transfer Proteins; Drug Discovery; Hydrogen Bonding; Ligands; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship; ROC Curve | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design.
Topics: | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches.
Topics: Amodiaquine; Antimalarials; Binding Sites; Catalytic Domain; Drug Design; Glucuronidase; Humans; Ligands; Molecular Docking Simulation; Nuclear Magnetic Resonance, Biomolecular; Quantitative Structure-Activity Relationship; Recombinant Proteins; Structure-Activity Relationship | 2013 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects.
Topics: Anti-Arrhythmia Agents; Astemizole; Biological Transport; Cation Transport Proteins; Cell Compartmentation; Cisapride; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Glycerol; Humans; Long QT Syndrome; Mutation; Patch-Clamp Techniques; Piperidines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Folding; Pyridines; Recombinant Proteins; Temperature; Trans-Activators; Transcriptional Regulator ERG | 1999 |
The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations.
Topics: Anti-Arrhythmia Agents; Astemizole; Benzimidazoles; Binding Sites; Blotting, Western; Cation Transport Proteins; Cell Line; Cell Membrane; Cisapride; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electrophysiology; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Gastrointestinal Agents; Histamine H1 Antagonists; Humans; Inhibitory Concentration 50; Ions; Long QT Syndrome; Models, Chemical; Mutagenesis, Site-Directed; Mutation; Patch-Clamp Techniques; Piperidines; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Folding; Pyridines; Quaternary Ammonium Compounds; Quinidine; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG | 2002 |
QT prolongation and safety in the Indian population.
Topics: Astemizole; Cisapride; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Histamine H1 Antagonists, Non-Sedating; Humans; India; Long QT Syndrome; Serotonin Receptor Agonists; Terfenadine; Torsades de Pointes | 2007 |
Protein binding-dependent decreases in hERG channel blocker potency assessed by whole-cell voltage clamp in serum.
Topics: Amiodarone; Animals; Astemizole; Blood Proteins; Cattle; Cell Line; Cisapride; Dialysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluvoxamine; Humans; Ion Channel Gating; Mice; Patch-Clamp Techniques; Potassium Channel Blockers; Protein Binding; Serum; Sodium Chloride; Thioridazine; Transfection | 2010 |
In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
Topics: Action Potentials; Anti-Arrhythmia Agents; Astemizole; Cisapride; Computer Simulation; Gene Expression; Genetic Predisposition to Disease; Heart Ventricles; Humans; Ion Channel Gating; Kinetics; Long QT Syndrome; Models, Statistical; Mutation; Phenethylamines; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Protein Conformation; Severity of Illness Index; Sotalol; Sulfonamides; Terfenadine | 2014 |